Sanofi: Q3 EPS down 11.5%
(CercleFinance.com) - Sanofi has reported business EPS of E2.
55 for Q3 2023, down 11.5% as reported and down 2.1% at CER, including the loss of Aubagio exclusivity.
At E11.96bn, the French healthcare group's sales were down 4.1% as reported, although were up 3.2% at CER, with the performance of specialty medicine and the strong start to the launches of Beyfortus and Altuviiio.
Sanofi confirms that it expects mid-single digit 2023 business EPS growth at CER, including one-off income of around E400m relating to its Covid vaccine in Q4.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
55 for Q3 2023, down 11.5% as reported and down 2.1% at CER, including the loss of Aubagio exclusivity.
At E11.96bn, the French healthcare group's sales were down 4.1% as reported, although were up 3.2% at CER, with the performance of specialty medicine and the strong start to the launches of Beyfortus and Altuviiio.
Sanofi confirms that it expects mid-single digit 2023 business EPS growth at CER, including one-off income of around E400m relating to its Covid vaccine in Q4.
Copyright (c) 2023 CercleFinance.com. All rights reserved.